Therapy Areas: Oncology
Celsius Therapeutics Names Kassum as Chief Executive Officer
14 June 2019 - - US-based Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for patients with autoimmune diseases and cancer, has appointed Tariq Kas...
Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma
14 June 2019 - - The US Food and Drug Administration has approved its PD-L1 IHC 22C3 pharmDx assay for expanded use, US-based Agilent Technologies Inc. (NYSE: A) said.
The assay is now appr...
Senti Biosciences Names Fischer as New Independent Board Member
14 June 2019 - - Dr. Laurent Fischer has joined US-based gene circuit company Senti Biosciences as an independent member of its board of directors, the company said.
Fischer is currently senior ...
Seattle Genetics Makes Multiple Adcetris Presentations at the Congress of the European Hematology Association and the International Conference on Malignant Lymphoma
14 June 2019 - - US-based biotechnology company Seattle Genetics, Inc. (NASDAQ: SGEN) is presenting data from its Adcetris (brentuximab vedotin) clinical development programme at the 24th An...
Prelude Therapeutics Secures USD 60m and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer
14 June 2019 - - US-based biopharmaceutical company Prelude Therapeutics has secured USD 60m in series B financing; taking its total investments to date to USD 95m, the company said.
The financi...
New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with US Merck's Keytruda in Patients with DLBCL
14 June 2019 - - Canadian immuno-oncology corporation IMV Inc. (NASDAQ: IMV) (TSX: IMV) has released updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV�...